Janssen Research & Development,
LLC, announced today that the U.S. Food and Drug Administration (FDA) has
granted Priority Review to the supplemental New Drug Application (sNDA) for
ZYTIGA^® (abiraterone acetate) administered in combination with prednisone for
the treatment of patients with metastatic castration-resistant prostate cancer
(mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen
deprivation therapy.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in